Your browser doesn't support javascript.
loading
Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties.
Puigseslloses, Pol; Nadal-Gratacós, Núria; Ketsela, Gabriel; Weiss, Nicola; Berzosa, Xavier; Estrada-Tejedor, Roger; Islam, Mohammad Nazmul; Holy, Marion; Niello, Marco; Pubill, David; Camarasa, Jordi; Escubedo, Elena; Sitte, Harald H; López-Arnau, Raúl.
Afiliación
  • Puigseslloses P; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section and Institute of Biomedicine (IBUB), Faculty of Pharmacy, University of Barcelona, 08028, Barcelona, Spain.
  • Nadal-Gratacós N; Pharmaceutical Chemistry Group (GQF), IQS School of Engineering, Universitat Ramon Llull, 08017, Barcelona, Spain.
  • Ketsela G; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section and Institute of Biomedicine (IBUB), Faculty of Pharmacy, University of Barcelona, 08028, Barcelona, Spain.
  • Weiss N; Pharmaceutical Chemistry Group (GQF), IQS School of Engineering, Universitat Ramon Llull, 08017, Barcelona, Spain.
  • Berzosa X; Pharmaceutical Chemistry Group (GQF), IQS School of Engineering, Universitat Ramon Llull, 08017, Barcelona, Spain.
  • Estrada-Tejedor R; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section and Institute of Biomedicine (IBUB), Faculty of Pharmacy, University of Barcelona, 08028, Barcelona, Spain.
  • Islam MN; Pharmaceutical Chemistry Group (GQF), IQS School of Engineering, Universitat Ramon Llull, 08017, Barcelona, Spain.
  • Holy M; Pharmaceutical Chemistry Group (GQF), IQS School of Engineering, Universitat Ramon Llull, 08017, Barcelona, Spain.
  • Niello M; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Wäehringerstrasse 13A, 1090, Vienna, Austria.
  • Pubill D; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Wäehringerstrasse 13A, 1090, Vienna, Austria.
  • Camarasa J; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, Wäehringerstrasse 13A, 1090, Vienna, Austria.
  • Escubedo E; Genetics of Cognition Lab, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genova, Italy.
  • Sitte HH; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section and Institute of Biomedicine (IBUB), Faculty of Pharmacy, University of Barcelona, 08028, Barcelona, Spain.
  • López-Arnau R; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Pharmacology Section and Institute of Biomedicine (IBUB), Faculty of Pharmacy, University of Barcelona, 08028, Barcelona, Spain.
Mol Psychiatry ; 29(8): 2346-2358, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38486047
ABSTRACT
Recent studies have sparked renewed interest in the therapeutic potential of psychedelics for treating depression and other mental health conditions. Simultaneously, the novel psychoactive substances (NPS) phenomenon, with a huge number of NPS emerging constantly, has changed remarkably the illicit drug market, being their scientific evaluation an urgent need. Thus, this study aims to elucidate the impact of amino-terminal modifications to the 5-MeO-DMT molecule on its interactions with serotonin receptors and transporters, as well as its psychoactive and thermoregulatory properties. Our findings demonstrated, using radioligand binding methodologies, that all examined 5-MeO-tryptamines exhibited selectivity for 5-HT1AR over 5-HT2AR. In fact, computational docking analyses predicted a better interaction in the 5-HT1AR binding pocket compared to 5-HT2AR. Our investigation also proved the interaction of these compounds with SERT, revealing that the molecular size of the amino group significantly influenced their affinity. Subsequent experiments involving serotonin uptake, electrophysiology, and superfusion release assays confirmed 5-MeO-pyr-T as the most potent partial 5-HT releaser tested. All tested tryptamines elicited, to some degree, the head twitch response (HTR) in mice, indicative of a potential hallucinogenic effect and mainly mediated by 5-HT2AR activation. However, 5-HT1AR was also shown to be implicated in the hallucinogenic effect, and its activation attenuated the HTR. In fact, tryptamines that produced a higher hypothermic response, mediated by 5-HT1AR, tended to exhibit a lower hallucinogenic effect, highlighting the opposite role of both 5-HT receptors. Moreover, although some 5-MeO-tryptamines elicited very low HTR, they still act as potent 5-HT2AR agonists. In summary, this research offers a comprehensive understanding of the psychopharmacological profile of various amino-substituted 5-MeO-tryptamines, keeping structural aspects in focus and accumulating valuable data in the frame of NPS. Moreover, the unique characteristics of some 5-MeO-tryptamines render them intriguing molecules as mixed-action drugs and provide insight within the search of non-hallucinogenic but 5-HT2AR ligands as therapeutical agents.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Serotonina / Receptor de Serotonina 5-HT2A / Simulación del Acoplamiento Molecular Límite: Animals / Humans / Male Idioma: En Revista: Mol Psychiatry Asunto de la revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Serotonina / Receptor de Serotonina 5-HT2A / Simulación del Acoplamiento Molecular Límite: Animals / Humans / Male Idioma: En Revista: Mol Psychiatry Asunto de la revista: BIOLOGIA MOLECULAR / PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido